A strategy for managing fungal infections in haematopoietic stem cell transplantation

Transplant Infectious Disease

Volumn 2, Issue 2, 2000, Pages 88-95

  Donnelly, J P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspergillus; Candida; Diagnosis; Empirical therapy; Fungal infection; Preemptive therapy; Prophylaxis; Stem cell transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FUNGUS ANTIGEN; ITRACONAZOLE; KETOCONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; FUNGUS CULTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; MICROSCOPY; MYCOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; PREVALENCE;

EID: 0034019686     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2000.020207.x     Document Type: Review

References (48)

1. LAROCCO MT, BURGERT SJ. Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev 1997: 10: 277-297.
2. WALSH TJ, HIEMENZ J, PIZZO PA. Evolving risk factors for invasive fungal infections - all neutropenic patients are not the same. Clin Infect Dis 1994: 18: 793-798.
3. WALD A, LEISENRING W, VAN BURIK JA, BOWDEN RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation [see comments]. J Infect Dis 1997: 175: 1459-1466.
4. COHEN J, DENNING DW, VIVIANI MA. Epidemiology of invasive aspergillosis in European cancer centres. EORTC Invasive Fungal Infections Cooperative Group [letter]. Eur J Clin Microbiol Infect Dis 1993: 12: 392-393.
5. NAKHLEH RE, BAKER PB, ZARBO RJ. Autopsy result utilization: a College of American Pathologists Q-probes study of 256 laboratories. Arch Pathol Lab Med 1999: 123: 290-295.
6. ASCIOGLU S, DE PAUW BE, BENNETT JE, et al. Analysis of definitions used in clinical research on invasive fungal infections (IFI): consensus proposal for new, standardized definitions. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1999: 573.
7. RINGDEN O, ANDSTROM EE, REMBERGER M, DAHLLOF G, SVAHN BM, TOLLEMAR J. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Pediatr Transplant 1997: 1: 124-129.
8. NOSKIN G, PIETRELLI L, GURWITH M, BOWDEN R. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant 1999: 23: 697-703.
9. LISTER J. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol Suppl 1996: 57: 18-23.
10. ANDSTROM EE, RINGDEN O, REMBERGER M, SVAHN BM, TOLLEMAR J. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996: 39: 185-193.
11. PERFECT JR, KLOTMAN ME, GILBERT CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992: 165: 891-897.
12. ROUSEY SR, RUSSLER S, GOTTLIEB M, ASH RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991: 91: 484-492
13. KARP JE, MERZ WG, CHARACHE P. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis 1991: 13: 592-599.
14. DENNING DW. Treatment of invasive aspergillosis. J Infect 1994: 28: 25-33.
15. GOODMAN JL, WINSTON DJ, GREENFIELD RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992: 326: 845-851.
16. WINGARD JR. The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. Leuk Lymphoma 1992: 8: 353-359.
17. BOOGAERTS MA, VERHOEF GE, ZACHEE P, DEMUYNCK H, VERBIST L, DE BEULE K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989: 32: 103-108.
18. GLASMACHER A, MOLITOR E, HAHN C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998: 12: 1338-1343.
19. PRENTICE AG, WARNOCK DW, JOHNSON SAN, PHILLIPS MJ, OLIVER DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994: 34: 247-252.
20. GUIOT HF, FIBBE WE, VANT WOUT JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis [see comments]. Clin Infect Dis 1994: 18: 525-532.
21. MARTINO P, GIRMENIA C, MICOZZI A, DEBERNARDIS F, BOCCANERA M, CASSONE A. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur J Clin Microbiol Infect Dis 1994: 13: 797-804.
22. MARTINO P, GIRMENUA C, VENDITTI M, et al. Candida colonization and systemic infection in neutropenic patients. Cancer 1989: 64: 2030-2034.
23. DE PAUW BE. Practical modalities for prevention of fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis 1997: 16: 32-41.
24. WEEMS JJ. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations and antibiotic susceptibility. Clin Infect Dis 1992: 14: 756-766.
25. ODDS FC, BERNAERTS R. CHROMagar candida, a new differential isolation medium for presumptive identification of clinically important candida species. J Clin Microbiol 1994: 32: 1923-1929.
26. RICHET HM, ANDREMONT A, TANCREDE C, PICO JL, JARVIS WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991: 13: 211-215.
27. Bow EJ, LOEWEN R, CHEANG MS, SCHACTER B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995: 21: 361-369.
28. WENZEL RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995: 20: 1531-1534.
29. JOHANSEN HK, GOTZSCHE PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999: 282: 1752-1759.
30. DE GREGORIO M, LEE W, RIES C. Candida infections in patients with acute leukaemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982: 50: 2780-2784.
31. MENICHETTI F, DELFAVERO A, MARTINO P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Internal Med 1994: 120: 913-918.
32. SLAVIN MA, OSBORNE B, ADAMS R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995: 171: 1545-1552.
33. SCHULER US, HAAG C. Prophylaxis of fungal infections. Mycoses 1997: 40: 41-44.
34. EDWARDS JE, Jr, BODEY GP, BOWDEN RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [see comments]. Clin Infect Dis 1997: 25: 43-59.
35. GUBBINS PO, BOWMAN JL, PENZAK SR. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients. Pharmacotherapy 1998: 18: 549-564.
36. GOTZSCHE PC, JOHANSEN HK. Meta analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. Br Med J 1997: 314: 1238-1244.
37. MORGENSTERN GR, PRENTICE AG, PRENTICE HG, ROPNER JE, SCHEY SA, WARNOCK DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999: 105: 901-911.
38. WARNOCK DW. Fungal infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother 1998: 41 (Suppl D): 95-105.
39. MARTINO P, RACCAH R, GENTILE G, VENDITTI M, GIRMENIA C, MANDELLI F. Aspergillus colonization of the nose and pulmonary aspergillosis in neutropenic patients: A retrospective study. Haematologica 1989: 74: 263-265.
40. BEHRE GF, SCHWARTZ S, LENZ K, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995: 71: 287-291.
41. ERJAVEC Z, WOOLTHUIS GM, DE VRIES. HOSPERS HG, et al. Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997: 16: 364-368.
42. CASTAGNOLA E, BUCCI B, MONTINARO E, VISCOLI C. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol. Bone Marrow Transplant 1996: 18 (Suppl 2): 97-106.
43. WALSH TJ, FINBERG RW, ARNDT C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group [see comments]. N Engl J Med 1999: 340: 764-771.
44. SEVERENS JL, DONNELLY JP, MEIS J, ROBBE PFD, DEPAUW BE, VERWEIJ PE. Two strategies for managing invasive aspergillosis: a decision analysis. Clin Infect Dis 1997: 25: 1148-1154.
45. LJUNGMAN P, LORE K, ASCHAN J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for preemptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996: 17: 583-587.
46. DENNING DW, MARINUS A, COHEN J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group J Infect 1998: 37: 173-180.
47. MAARTENS G, WOOD MJ. The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother 1991: 28: 13-22.
48. VERWEIJ PE, DONNELLY JP, DE PAUW BE, MEIS JFGM. Prospects for the early diagnosis of invasive aspergillois in the immunocompromised host. Rev Med Microbiol 1996: 7: 105-113.